- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03091361
Post Market Clinical Followup of MolecuLight i:X's PPV to Predict Presence of Bacteria in Wounds
A Prospective, Single-blind Evaluation of the Positive Predictive Value (PPV) of the MolecuLight i:X™ Imaging Device to Predict the Presence of Bacteria in Chronic Wounds
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
MolecuLight Inc. (Toronto, Canada) has recently introduced to the Canadian market an innovative imaging device, the MolecuLight i:X™ Imaging Device, that offers real-time detection of important biological and molecular information of a chronic wound, and could have significant impact on improving conventional wound care and management. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the chronic wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present. Though the MolecuLight i:X Imaging Device has been shown to be effective in controlled settings, this study is deploying the device in a larger population and evaluating the ability of the MolecuLight i:X device to positively predict the presence of bacteria in chronic wounds.
The overall objective of this work is to evaluate the MolecuLight i:X Imaging Device in screening of chronic wounds for the presence of bacteria. The device is intended to guide the clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
All imaging will be performed with the MolecuLight i:X Imaging Device at an appropriate distance from the wound of interest (8 - 12 cm), which is indicated by the range finder LED. Illumination is provided by two violet (405 nm) LEDs that produce a bright, but clinically safe, uniform illumination. Fluorescence imaging is performed on the camera in real-time while the device is in fluorescence mode and the room lights are turned off. If room ambient light cannot be eliminated to an acceptable level (indicated by the ambient light sensor), the MolecuLight drape must be used to achieve a dark environment. A standard measurement sticker will be placed adjacent to the wound within the field of view to act as a reference for size.
All microbiological analysis will be performed as per clinic standard practice. Tissue samples will be analyzed for culture and sensitivity, yielding the species of bacteria present in the sample (if any), the susceptibility to various antibiotics and a measure of the bacterial load.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
North York, Ontario, Canada, M2R 1N5
- Judy Dan Research and Treatment Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- presents with a chronic wound of the lower limb (e.g. diabetic foot ulcer, venous leg ulcer, other acceptable aetiology)
- red or cyan fluorescence signals observed within or around wound on MolecuLight i:X images
Exclusion Criteria:
- Treatment with an investigational drug within 1 month before study enrollment
- Use of systemic (oral or intravenous) antibiotics
- Inability to consent to medical photography
- Any contra-indication to routine wound care and/or monitoring
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
All patients (imaging/no intervention)
There is only one group in this study, the imaging/no intervention group.
These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device.
A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis.
There will be no intervention or followup.
|
no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive Predictive Value (PPV) of Localized Red Fluorescence Signals With Microbiological Samples
Time Frame: 3 months
|
PPV reflects the probability that a region of red fluorescence within or around a wound will contain bacteria.
Meaning the number cases where qPCR analysis of wound tissue biopsies from red fluorescent region showed to have pathogen load ≥ 104 CFU/g divided by the total number of cases where red florescence was observed in the wound multiplied by 100,
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ron Linden, MD, Judy Dan Research and Treatment Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wounds and Injuries
-
3MWithdrawn
-
Centre Hospitalier Universitaire de NīmesCompletedWounds and Injuries, Hands | Wounds and Injuries, Wrists | Wounds and Injuries, Feet | Wounds and Injuries, AnklesFrance
-
Samsung Medical CenterCompletedNeedle Stick InjuriesKorea, Republic of
-
Assaf-Harofeh Medical CenterUnknownInjuries and Wounds
-
Karolinska InstitutetCompletedWounds and Injuries | Blast Injuries | War-Related Injuries | Gunshot WoundSweden
-
Medical University of South CarolinaCompletedNeedlestick InjuriesUnited States
-
Hospital Universiti Sains MalaysiaActive, not recruiting
-
Temple UniversityWithdrawnLacerations | Injuries | WoundsUnited States
-
Acibadem UniversityCompletedNeedlestick InjuriesTurkey
Clinical Trials on imaging, no intervention
-
Carmel Medical CenterEuropean Foundation for the Study of DiabetesUnknown
-
University of MinnesotaNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
Aristotle University Of ThessalonikiRecruitingMetalloproteinase SNPs -1575 G/A MMP-2, 836 A/G MMP-9 and -77 A/G MMP-13 and Risk for Developing Knee Osteoarthritis in Greek PopulationGreece
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada